non-small cell lung cancer
Conditions
Interventions
Observation group:None
Sponsors
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male or female patients aged 18 years or older (no upper age limit). 2. Patients with histologically or cytologically proven advanced NSCLC (including those with positive driver genes who failed or could not tolerate TKI therapy). 3. Subjects must have measurable lesions on imaging (CT, MRI, PET-CT, etc.) according to RECIST 1.1. 4. Those who have not received standard therapy before or have failed standard therapy and/or cannot tolerate standard therapy. 5. The subjects voluntarily joined the study and signed the informed consent, with good compliance and cooperation in follow-up.
Exclusion criteria
Exclusion criteria: 1. The estimated survival time is less than 3 months. 2. Previous treatment with anti-tumor vaccines or other immune-stimulating anti-tumor drugs. 3. Previous treatment with anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug that specifically acts on the T-cell costimulation or checkpoint pathway). 4. The patient is undergoing other trials and is prohibited from concomitant drug treatment, and the drug cannot be stopped during the study. 5. In the opinion of the investigator, the patient's medical history or concurrent conditions may affect the patient's ability to comply with the trial. 6. Other conditions deemed inappropriate for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Imaging efficacy evaluation; | — |
Countries
China
Contacts
Public ContactHaihua Yuan
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed